BUZZ-重新提交眼疾药物申请后，Aldeyra 公司业绩上涨

Reuters10-03

((自动化翻译由路透提供，请见免责声明 ))

10月3日 - ** Aldeyra Therapeutics 股价盘前上涨 1.9% 至 5.40 美元

** 该公司称已向美国食品及药物管理局重新提交了干眼症药物的审批申请

** 去年，美国食品和药物管理局拒绝批准 (link) 药物 reproxalap

** 截至上次收盘，股价累计上涨 51

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2472690619?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-03 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2472690619","market":"us","top_or_hot":-1,"title":"BUZZ-重新提交眼疾药物申请后，Aldeyra 公司业绩上涨","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    10月3日 - ** Aldeyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>    股价盘前上涨 1.9% 至 5.40 美元</p><p>** 该公司称已向美国食品及药物管理局重新提交了干眼症药物的审批申请</p><p>** 去年，美国食品和药物管理局拒绝批准 (link) 药物 reproxalap </p><p>** 截至上次收盘，股价累计上涨 51 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-重新提交眼疾药物申请后，Aldeyra 公司业绩上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-重新提交眼疾药物申请后，Aldeyra 公司业绩上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-03 20:42 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    10月3日 - ** Aldeyra Therapeutics    股价盘前上涨 1.9% 至 5.40 美元** 该公司称已向美国食品及药物管理局重新提交了干眼症药物的审批申请** 去年，美国食品和药物管理局拒绝批准 (link) 药物 reproxalap ** 截至上次收盘，股价累计上涨 51</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALDX","symbol_name":"Aldeyra Therapeutics Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2472690619","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472690619","pubTimestamp":1727959340,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自动化翻译由路透提供，请见免责声明 ))    10月3日 - ** Aldeyra Therapeutics    股价盘前上涨 1.9% 至 5.40 美元** 该公司称已向美国食品及药物管理局重新提交了干眼症药物的审批申请** 去年，美国食品和药物管理局拒绝批准 (link) 药物 reproxalap ** 截至上次收盘，股价累计上涨 51","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","BK4139":"生物科技"},"translate_title":"BUZZ-Aldeyra Inc. Results Rise After Resubmitting Eye Disease Drug Application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    10月3日 - ** Aldeyra Therapeutics    股价盘前上涨 1.9% 至 5.40 美元** 该公司称已向美国食品及药物管理局重新提交了干眼症药物的审批申请** 去年，美国食品和药物管理局拒绝批准 (link) 药物 reproxalap ** 截至上次收盘，股价累计上涨 51","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472690619"}